I sit down with Marina Udier, CEO of Nouscom, a Swiss company working on the Lynch Syndrome vaccine. Nous209 is designed to intercept tumors in Lynch Syndrome cancers. The 209 comes from the frameshifts of neoantigens, whether sporadic or hereditary. Idea is to educate the T-cells before cancers start forming. The data at AACR presented was very promising. They are also running a study on metastatic colorectal cancer patients, mostly without Lynch Syndrome, but MSI high. So how many people are tested positive for Lynch Syndrome each year? Next steps includes additional investigators and patients for a much bigger trial, at a time to be determined, and of course funding is always a priority. Suffice it so say, interest is high is seeing this come to late stage development.
